~~<i id='79C6794FC2'><strike id='79C6794FC2'><tt id='79C6794FC2'><pre id='79C6794FC2'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：entertainment 2025-10-06 16:18:25 Page View：8

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： For Medicare Advantage, Democrats want stronger protections around AI
Next article： Apple is now the first public company to be valued at $3 trillion

knowledge

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Medicare threatens to cut off funding for HCA's Mission hospital

MikeBellemeforSTATFiveyearsafterinvestor-ownedHCAHealthcaretookoveranesteemednonprofithospitalinNort

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

Some of the ways extreme heat will change life as we know it

1:18AtourguidefansherselfwhileworkinginTimesSquareastemperaturesrise,July27,2023,inNewYorkCity.JohnM